Silence Therapeutics Reports Q1 2026 Revenue Growth to $422,000 Amid Continued Net Loss

Silence Therapeutics plc reported its financial results for the first quarter of 2026, revealing a revenue of $422,000, a significant increase from $142,000 in the same period of 2025. This growth is attributed to activities related to the company's collaboration with AstraZeneca, which has been a key driver of revenue generation. The company reported a gross profit of $411,000, compared to $88,000 in the prior year, reflecting improved operational efficiency. Despite the increase in revenue, Silence Therapeutics continued to experience a net loss of $14.96 million, although this was a notable reduction from the $28.53 million loss reported in the first quarter of 2025.

The company's total current assets decreased to $102.85 million as of March 31, 2026, down from $118.66 million at the end of 2025. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $5.66 million from $11.28 million. The decrease in cash reserves is indicative of ongoing operational expenditures, as the company continues to invest heavily in research and development. Research and development costs for the quarter were $9.12 million, significantly lower than the $20.81 million spent in the same period last year, largely due to decreased contracted development costs associated with the zerlasiran Phase 3 readiness.

Operationally, Silence Therapeutics has made strategic adjustments, including a shift in the functional currency of its U.K. entity from British pounds to U.S. dollars, effective January 1, 2026. This change is expected to streamline financial reporting and mitigate foreign exchange risks. The company also reported a decrease in general and administrative expenses, which fell to $7.03 million from $7.68 million, reflecting ongoing efforts to manage costs effectively. As of March 31, 2026, the company had a total of 141.70 million ordinary shares outstanding, a slight increase from 141.70 million at the end of 2025.

Looking ahead, Silence Therapeutics anticipates continued investment in its product pipeline, particularly in RNA therapeutics, as it seeks to advance its clinical programs. The company has sufficient cash and short-term investments, totaling $70.1 million, to fund its operations into 2028. However, it acknowledges the need for additional funding to support ongoing research and development activities and to meet future operational requirements. The company remains focused on achieving regulatory approvals for its product candidates and is exploring various financing options, including potential collaborations and public offerings, to ensure its long-term viability.